Equities

Bicycle Therapeutics PLC

Bicycle Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.54
  • Today's Change0.28 / 1.38%
  • Shares traded536.42k
  • 1 Year change+48.63%
  • Beta0.8750
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments526339439
Total Receivables, Net242112
Total Inventory------
Prepaid expenses119.027.97
Other current assets, total------
Total current assets562369459
Property, plant & equipment, net283318
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets5.798.463.45
Total assets595411480
LIABILITIES
Accounts payable136.472.72
Accrued expenses312514
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total252220
Total current liabilities705336
Total long term debt313030
Total debt313030
Deferred income tax------
Minority interest------
Other liabilities, total1245667
Total liabilities224140134
SHAREHOLDERS EQUITY
Common stock0.550.390.38
Additional paid-in capital883601568
Retained earnings (accumulated deficit)(512)(331)(218)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(1.3)0.39(3.39)
Total equity371271346
Total liabilities & shareholders' equity595411480
Total common shares outstanding423030
Treasury shares - common primary issue------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.